Atlas Trials

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Clinical trial NCT00292760 · COMPLETED

Trial details

NCT number
NCT00292760
Sponsor
Royal Marsden NHS Foundation Trust
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukaemia

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.